|
AstraZeneca PLC on Tuesday said that its immunotherapy Imfinzi showed positive survival rate in people with advanced biliary tract cancer. The Cambridge, England-based pharmaceutical company said Imfinzi plus chemotherapy showed a clinically meaningful long-term overall survival benefit at three years for patients with advanced biliary tract cancer. Imfinzi is a US Food & Drug Administration-approved immunotherapy for cancer, that blocks the interaction of programmed cell death ligand 1 with the PD-1. At more than three years, Imfinzi plus chemotherapy reduced the risk of death by 26% compared to chemotherapy alone, with an overall median survival rate of 12.9 months for Imfinzi plus chemotherapy compared to 11.3 months for chemotherapy. ‘These results reinforce the long-term benefit of this immunotherapy-based combination as a standard of care for patients with this devastating disease,’ said Do-Youn Oh, professor at the division of Medical Oncology, Department of Internal Medicine at Seoul National University Hospital and Seoul National University College of Medicine, and principal investigator in the trial. AstraZeneca shares were 0.8% lower at 10,934.00 pence each on Tuesday morning in London. Copyright 2024 Alliance News Ltd. All Rights Reserved.
|
